t⁶A and ms²t⁶A Modified Nucleosides in Serum and Urine as Strong Candidate Biomarkers of COVID-19 Infection and Severity

• الحاوية / القاعدة: Biomolecules
• المؤلفون الرئيسيون: Yu Nagayoshi, Kayo Nishiguchi, Ryosuke Yamamura, Takeshi Chujo, Hiroyuki Oshiumi, Hiroko Nagata, Hitomi Kaneko, Keiichi Yamamoto, Hirotomo Nakata, Korin Sakakida, Akihiro Kunisawa, Masataka Adachi, Yutaka Kakizoe, Takanori Mizobe, Jun-ichi Kuratsu, Shinya Shimada, Yasushi Nakamori, Masao Matsuoka, Masashi Mukoyama, Fan-Yan Wei, Kazuhito Tomizawa
• التنسيق: مقال
• اللغة: الإنجليزية
• منشور في: MDPI AG 2022-09-01
• الموضوعات: COVID-19; modified nucleosides; LC-MS
• الوصول للمادة أونلاين: https://www.mdpi.com/2218-273X/12/9/1233
• تدمد: 2218-273X

SARS-CoV-2 infection alters cellular RNA content. Cellular RNAs are chemically modified and eventually degraded, depositing modified nucleosides into extracellular fluids such as serum and urine. Here we searched for COVID-19-specific changes in modified nucleoside levels contained in serum and urine of 308 COVID-19 patients using liquid chromatography-mass spectrometry (LC-MS). We found that two modified nucleosides, <i>N</i>⁶-threonylcarbamoyladenosine (t⁶A) and 2-methylthio-<i>N</i>⁶-threonylcarbamoyladenosine (ms²t⁶A), were elevated in serum and urine of COVID-19 patients. Moreover, these levels were associated with symptom severity and decreased upon recovery from COVID-19. In addition, the elevation of similarly modified nucleosides was observed regardless of COVID-19 variants. These findings illuminate specific modified RNA nucleosides in the extracellular fluids as biomarkers for COVID-19 infection and severity.